Evaluasi Terapi Farmakologi pada Pasien Diabetes Melitus Tipe 2 dengan Hipertensi dan Hiperlipidemia di UPT Puskesmas X Kota Pekanbaru

Authors

  • Adriani Susanty Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau
  • Effy Mutia Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau
  • Dzaskia Arriva Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau
  • Elizabeth Kartika LN Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau
  • Marlina Alfitrah Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau
  • Melysha Suci Putri Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau
  • Rinta Maspat Program Studi Profesi Apoteker, Sekolah Tinggi Ilmu Farmasi Riau

DOI:

https://doi.org/10.31004/joecy.v6i3.14604

Keywords:

Type 2 Diabetes Mellitus, Hypertension, Hyperlipidemia, Pharmacological Therapy, Drug Evaluation.

Abstract

Type 2 diabetes mellitus (T2DM) accompanied by comorbid hypertension and hyperlipidemia requires appropriate treatment to achieve control over glucose levels, blood pressure, and lipid profiles. This study was conducted to assess the appropriateness of medication use for a patient with T2DM, hypertension, and hyperlipidemia at Community Health Center X in Pekanbaru. A descriptive study design was employed, involving a review of patient data, diagnoses, treatments, and clinical and laboratory test results. The patient in this case was a 45-year-old male weighing 65 kg and standing 168 cm tall, resulting in a body mass index (BMI) of 23.03 kg/m². Laboratory tests revealed a fasting blood glucose level of 221 mg/dL, total cholesterol of 246 mg/dL, LDL of 138 mg/dL, HDL of 44 mg/dL, and triglycerides of 322 mg/dL. The pharmacological therapy prescribed consisted of amlodipine 5 mg once daily, simvastatin 20 mg once daily, metformin 500 mg twice daily, glimepiride 2 mg once daily, and thiamine HCl once daily. The assessment concluded that the prescribed medications aligned with the patient's therapeutic needs regarding the appropriateness of the indication, drug selection, dosage, and the patient's condition. Furthermore, no contraindications or drug-related problems were identified during the evaluation.

References

American Diabetes Association. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Suppl. 1).

DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2017). Pharmacotherapy: A pathophysiologic approach (10th ed.). McGraw-Hill Education.

Kementerian Kesehatan Republik Indonesia. (2019). Pedoman pelayanan kefarmasian pada diabetes melitus. Kementerian Kesehatan RI.

Perhimpunan Dokter Hipertensi Indonesia. (2021). Konsensus penatalaksanaan hipertensi. Perhimpunan Dokter Hipertensi Indonesia.

Perkumpulan Endokrinologi Indonesia. (2019). Panduan pengelolaan diabetes melitus tipe 2 di Indonesia. PB PERKENI.

Perkumpulan Endokrinologi Indonesia. (2021). Panduan pengelolaan dislipidemia. PB PERKENI.

Perkumpulan Endokrinologi Indonesia. (2024). Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. PB PERKENI.

Unger, T., Borghi, C., Charchar, F., et al. (2020). 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension, 75(6), 1334–1357.

World Health Organization. (2025a). Hypertension. World Health Organization.

World Health Organization. (2025b). Noncommunicable diseases. World Health Organization.

Downloads

Published

16-11-2026

How to Cite

Susanty, A. ., Mutia, E. ., Arriva, D. ., LN, E. K. ., Alfitrah, M. ., Putri, M. S. ., & Maspat, R. . (2026). Evaluasi Terapi Farmakologi pada Pasien Diabetes Melitus Tipe 2 dengan Hipertensi dan Hiperlipidemia di UPT Puskesmas X Kota Pekanbaru. Journal of Innovative and Creativity, 6(3), 52109–52113. https://doi.org/10.31004/joecy.v6i3.14604

Issue

Section

Articles